Open Access
Performance standards for antimicrobial susceptibility testing
Reads0
Chats0
TLDR
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.Abstract:
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016. The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition are followed.read more
Citations
More filters
Journal ArticleDOI
Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98.
TL;DR: From November 1997 to April 1998, 1,601 clinical isolates of Streptococcus pneumoniae were obtained from 34 U.S. medical centers and resistance to all 10 ss-lactam drugs examined in this study was directly related to the level of penicillin resistance.
Journal ArticleDOI
Aeromonas spp. and Traveler’s Diarrhea: Clinical Features and Antimicrobial Resistance
Jordi Vila,Joaquín Ruiz,Francisco Gallardo,Martha Vargas,L. Soler,Maria José Figueras,Joaquín Gascón +6 more
TL;DR: Aeromonas spp.
Journal ArticleDOI
Comparative Evaluation of the VITEK 2, Disk Diffusion, Etest, Broth Microdilution, and Agar Dilution Susceptibility Testing Methods for Colistin in Clinical Isolates, Including Heteroresistant Enterobacter cloacae and Acinetobacter baumannii Strains
Jerome R. Lo-Ten-Foe,Anne Marie G. A. de Smet,Bram M. W. Diederen,Jan Kluytmans,Peter H. J. van Keulen +4 more
TL;DR: The VITEK 2 colist in susceptibility test can be considered to be a reliable tool to determine susceptibility to colistin in isolates of genera that are known not to exhibit resistant subpopulations.
Journal ArticleDOI
Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones
Gabriel Cabot,Alain A. Ocampo-Sosa,M. Angeles Domínguez,Juan F. Gago,Carlos Juan,Fe Tubau,Cristina Rodríguez,Bartolomé Moyá,Carmen Peña,Luis Martínez-Martínez,Antonio Oliver +10 more
TL;DR: Of particular interest, in nearly all the ST175 isolates, AmpC hyperproduction was driven by a novel AmpR-activating mutation (G154R), as demonstrated by complementation studies using an ampR mutant of PAO1.
Journal ArticleDOI
Emergence of Daptomycin Resistance in Enterococcus faecium during Daptomycin Therapy
TL;DR: A 22-year-old man with Hodgkin's lymphoma, subsequent acute myelogenous cancer and a clinical and bacteriological failure of daptomycin therapy for enterococcal bacteremia are reported.